Kennedy Capital Management LLC Has $28.23 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Kennedy Capital Management LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 14.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,209,692 shares of the biopharmaceutical company’s stock after acquiring an additional 149,485 shares during the period. Catalyst Pharmaceuticals makes up about 0.6% of Kennedy Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Kennedy Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $28,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC raised its holdings in Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,520 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares in the last quarter. Clearstead Advisors LLC raised its holdings in Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 1,167 shares in the last quarter. Larson Financial Group LLC raised its holdings in Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,564 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $39,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CPRX has been the subject of several analyst reports. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Finally, HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $31.36 on Friday. The stock has a market capitalization of $3.84 billion, a P/E ratio of 18.02, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The stock has a fifty day moving average of $29.16 and a 200-day moving average of $25.63.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).